Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06721624 · ClinicalTrials.gov registry record

Prospective Observational Study of Naturopathic Approaches to IBS

A clinical trial of Irritable Bowel Syndrome (IBS), sponsored by National University of Natural Medicine.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06721624: Recruiting study of Irritable Bowel Syndrome (IBS), sponsored by National University of Natural Medicine.

NCT06721624 is a study of Irritable Bowel Syndrome (IBS) that is actively recruiting participants, run by National University of Natural Medicine. The registered enrollment target is 50 participants, below the 1,179-participant average among 5 other Irritable Bowel Syndrome (IBS) trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06721624, a study of Irritable Bowel Syndrome (IBS), is actively recruiting participants, sponsored by National University of Natural Medicine.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Irritable bowel syndrome (IBS) is a common condition affecting about 4% of people worldwide and can significantly impact quality of life and healthcare costs. While there are medications available, few are consistently effective, leading many people with IBS to explore alternative treatments, including naturopathy. However, research on naturopathic approaches to IBS is limited. This study aims to describe how naturopathy is used to treat IBS and to collect preliminary data on changes in IBS symptoms before and after treatment. It will use a prospective, observational design without a control group, focusing on outcomes from individualized naturopathic care provided by licensed practitioners. Adult patients with diagnosed IBS or IBS-like symptoms will be recruited from naturopathic doctors affiliated with the Gastroenterology Association of Naturopathic Physicians. Participants' IBS symptoms will be assessed using validated tools (IBS-SSS and IBS-AR), and quality of life will be measured using the PROMIS-29 survey. Treatment details and any adverse effects will also be recorded. The main outcome will be the difference in symptoms and quality of life after 12 weeks of treatment. Results will be analyzed with statistical tests (p-value \< 0.05) and summarized. The findings from this pilot study will help fill knowledge gaps and provide a foundation for designing a more rigorous randomized controlled trial in the future.

Primary Outcome

IBS-SSS

Conditions Studied

Irritable Bowel Syndrome (IBS)

Interventions

  • OTHER Naturopathic medicine

Study Locations (1)

Oregon

  • Helfgott Research Institute - National University of Natural Medicine - Portland

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-11-01
Est. Completion 2025-11
National University of Natural Medicine

30 total trials

What NCT06721624 shows while recruiting

NCT06721624 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,179-participant average among 5 other Irritable Bowel Syndrome (IBS) trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Irritable Bowel Syndrome (IBS) appearing as the primary indexed condition, and to 1 intervention - of which Naturopathic medicine is the first listed.

NCT06721624 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT06721624 about?

NCT06721624 is a clinical study titled "Prospective Observational Study of Naturopathic Approaches to IBS". Irritable bowel syndrome (IBS) is a common condition affecting about 4% of people worldwide and can significantly impact quality of life and healthcare costs. While there are medications available, few are consistently effective, leading many people with IBS to explore alternative treatments, includ...

What is the current status of trial NCT06721624?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-11-01. Estimated completion is 2025-11.

What conditions does trial NCT06721624 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome (IBS).

What interventions are being tested in trial NCT06721624?

The interventions under investigation include: Naturopathic medicine (OTHER).

Who is sponsoring clinical trial NCT06721624?

This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06721624 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Irritable Bowel Syndrome (IBS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06721624

Source: ClinicalTrials.gov NCT06721624, the US trial registry maintained by the National Library of Medicine. NCT06721624 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.